VEGF stimulation enhances livin protein synthesis through mTOR signaling

Journal of Cellular Biochemistry

Volumn 111, Issue 5, 2010, Pages 1114-1124

  Yan, Biao ^a,b   Kong, Men ^b   Chen, Shi ^b   Chen, Yi Han ^a,c,d  

^a TONGJI UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

4E BP1; Livin; mTOR; Rapamycin; VEGF

Indexed keywords

CYTOTOXIC AGENT; LIVIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; VASCULOTROPIN;

ABLATION THERAPY; AGGRESSION; ARTICLE; BACTERIAL GENE; CANCER THERAPY; CELL VIABILITY; GENETIC TRANSCRIPTION; GROWTH; HELA CELL; HUMAN; HUMAN CELL; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STIMULATION; TRANSLATION INITIATION; TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; HELA CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

INTRACISTERNAL A-PARTICLES;

EID: 78649820615     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22797     Document Type: Article

References (38)

1. Beierle EA, Nagaram A, Dai W, Iyengar M, Chen MK,. 2005. VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res 127 (1): 21-28.
2. Boaz N, Yaqoub A, Vered B, Olga D, Luna K, Michal L, Tamar P, Ofer M, Dina B,. 2003. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 63 (19): 6340-6349.
3. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT,. 1996. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15 (19): 5256-5267.
4. Chang H, Schimmer A,. 2007. Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 6 (1): 24-30.
5. Chen L, Ren G, Li F, Sun S,. 2008. Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol 14 (37): 5749-5754.
6. Clemens MJ,. 2001. Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins. J Cell Mol Med 5: 221-239.
7. CrnkoviÄ-Mertens I, Semzow J, Hoppe-Seyler F, Butz K,. 2006. Isoform-specific silencing of the Livin gene by RNA interference defines Livin as key mediator of apoptosis inhibition in HeLa cells. J Mol Med 84 (3): 232-240.
8. Dasgupta A, Peirce S, Findley H,. 2009. MycN is a transcriptional regulator of livin in neuroblastoma. Oncol Rep 22 (4): 831-835.
9. Gingras A, Kennedy S, O'Leary M, Sonenberg N, Hay N,. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Gene Dev 12 (4): 502-513.
10. Gingras AC, Raught B, Sonenberg N,. 1999. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68 (1): 913-963.
11. Gingras A, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N,. 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15: 2852-2864.
12. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP,. 1999. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247 (2): 495-504.
13. Hao W, Sheng-shun T, Xin-yang W, Dong-hua L, Chun-shui Y, Zhuan-li B, Da-lin H, Jun Z,. 2007. Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells. Acta Pharmacol Sin 28 (12): 1968-1974.
14. Hay N, Sonenberg N,. 2004. Upstream and downstream of mTOR. Gene Dev 18 (16): 1926-1945.
15. Hicklin D, Ellis L,. 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (5): 1011-1027. (Pubitemid 46202320)
16. Hunter A, LaCasse E, Korneluk R,. 2007. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12 (9): 1543-1568.
17. Jiang W, Zhu Z, Thompson H,. 2008. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 68 (13): 5492-5499.
18. Kasof GM, Gomes BC,. 2001. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276: 3238-3246.
19. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL,. 2004. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 104 (9): 2886-2892.
20. Lin J, Deng G, Huang Q, Morser J,. 2000. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun 279: 820-831.
21. Liu B, Han M, Wen JK, Wang L,. 2007. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 250: 168-176.
22. Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, Edenhofer F, Kiyama H, Yonezawa K, Yamanaka S,. 2004. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24 (15): 6710-6718.
23. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA,. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
24. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L,. 2006. VEGF receptor signalling? In control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
25. Reynolds T, Bodine S, Lawrence J,. 2002. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 277 (20): 17657-17662.
26. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M,. 2004. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 23: 4624-4635.
27. Rumble J, Duckett C,. 2008. Diverse functions within the IAP family. J Cell Sci 121 (21): 3505-3507.
28. Salvesen GS, Duckett CS,. 2002. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410.
29. Sarbassov D, Ali S, Sabatini D,. 2005. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17 (6): 596-603.
30. Tammela T, Enholm B, Alitalo K, Paavonen K,. 2005. The biology of vascular endothelial growth factors. Cardiovasc Res 65 (3): 550-563.
31. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC,. 2006. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684.
32. Vucic D, Stennicke H, Pisabarro M, Salvesen G, Dixit V,. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10 (21): 1359-1366.
33. Wang L, Chen L, Benincosa J, Fortney J, Gibson LF,. 2005. VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli. Leukemia 19: 344-353.
34. Wilson JE, Pestova TV, Hellen CUT, Sarnow P,. 2000. Initiation of protein synthesis from the A site of the ribosome. Cell 18 (4): 511-520.
35. Wullschleger S, Loewith R, Hall MN,. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484.
36. Ylä-Herttuala S, Rissanen T, Vajanto I, Hartikainen J,. 2007. Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49 (10): 1015-1026.
37. Yuan D, Liu L, Gu D,. 2007. Transcriptional regulation of livin by β-catenin/TCF signaling in human lung cancer cell lines. Mol Cell Biochem 306 (1): 171-178.
38. Zhang B, Wen-Hua Z, Wu-Yuan Z, Wen-Sheng Y, Sheng L,. 2007. Expression of vascular endothelial growth factors-C and-D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma. Cancer Detect Prev 31 (6): 436-442.